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Ethics of surgical innovation to treat rare diseases
James W. Jones, MD, PhD, MHA,a Laurence B. McCullough, PhD,a and Bruce W. Richman, MA,bHouston, Tex; and Columbia, MoA gynecologist has referred you a 50-year-old
woman with extensive intravenous leiomyomatosis. A
tissue diagnosis of invasive low-grade malignancy is
available, and the tumor extends into the renal and
hepatic veins. You propose removing the tumor by
hysterectomy, to be combined if necessary with an
extensive venectomy. The patient has had multiple vas-
cular procedures which have exhausted all her available
autologous graft material. You will try to excise the
tumor through a venotomy, but it is likely that recon-
struction will require venous replacement with pros-
thetic material, for which you have chosen externally
supported polytetrafluoroethylene. What is the ethical
course of action?
A. Initiate an especially detailed informed consent process,
stressing the uncertainties and increased risks of such an
operation.
B. Advise the patient that the prognosis is not good, but
there is no other choice.
C. Provide a generalized description of what you propose.
Technical details that may upset the patient are not
necessary.
D. Obtain informed consent and apply to the institutional
review board (IRB) for approval of an experimental
procedure.
E. Obtain informed consent and IRB approval, and con-
sult with the ethics committee.
Since ancient times, surgeons have individualized ther-
apy to one degree or another without seeking supervision
or prior approval by third parties. Past murmurings about
excessive surgical autonomy, however, have culminated in
recent calls for regulation of “significant” innovations.1,2
Surgeons exercise autonomous judgment when they select,
titrate, or discontinue medications, prophylactic antibiot-
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doi:10.1016/j.jvs.2004.01.003918ics, and prep solutions; make transfusion decisions, incise,
and anastomose; or choose a suture material and the way to
tie it. These are judgments made in consideration of each
patient’s condition, clinical indications, and the surgeon’s
personal experience and preference for materials with which
he has familiarity and confidence. When treatment pro-
ceeds without complication, such idiosyncrasies are well
within the range of normal variation seen in every practice.
Neither individual preferences nor autonomy are problem-
atic in and of themselves when the surgeon is using mate-
rials and techniques that will afford his patient a highly
predictable therapeutic result. The decision-making au-
thority to implement innovations, understood as adjust-
ments to existing norms, is granted to the surgeon by the
culture and by the patient. This authority is based substan-
tially upon the understanding that the surgeon has com-
pleted a course of accredited training, has accumulated
some experience, and is well prepared to make such judg-
ments in order to achieve a favorable treatment outcome.
The patient’s provision of informed consent for the opera-
tion described is typically supplemented by the standard
phrase “and all other necessary procedures,” and confers
upon the surgeon the wide discretionary latitude he needs
to manage unforeseen complications or occult pathology
revealed intraoperatively. To evaluate the boundaries of this
latitude, we must distinguish between innovation and ex-
perimentation.
Defining our limits requires us to define our terms.
What, then, do we mean by “surgical innovation”? The
Oxford English Dictionary’s etymology of “innovation”
offers the Latin root “innovatus,” to renew or alter, imply-
ing revision or modification of something that is already
established. If one accepts the limitations this definition
places on the word “innovation,” most innovation is not
only acceptable but also desirable. Alternatively, innovation
is recognized as the introduction of something entirely
new. From this point of view, the phrase “surgical innova-
tion” suggests necessary and desirable features as well as
some that may be unnecessary and undesirable. Every sur-
geon has a clear idea of personal boundaries, but it is safe to
say that the limits of acceptable innovation are neither
widely accepted nor closely observed by the profession at
large.3
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surgery and concluded that the different nature of the
informed consent can provide a test of whether a new
treatment is experimental.The consent process in conven-
tional treatment includes a discussion of what is known, but
in experimental treatment the discussion must concentrate
upon what is not known. When uncertainty of outcome
enters the informed consent process, the concept of exper-
imentation becomes a consideration. Because the present
case involves a malignancy, experimental therapy is clearly
indicated, but one should remember that, when not indi-
cated, such therapy is “reckless experimentation.” In rarely
done procedures, the surgeon must evaluate whether data
developed to resolve the uncertainty is sufficient and ade-
quately studied to predict outcome of the proposed ther-
apy. The patient always should be told how many such
procedures the surgeon has done, as well as the associated
morbidity and mortality rates. It is not enough to cite the
statistics of other surgeons and institutions with similar
procedures. When engaging in planned experimentation,
the surgeon is obligated to obtain permission from the
patient or his surrogate, after providing transparent disclo-
sure of the uncertainty of outcome when appropriate to the
operative conditions. If circumstances do not permit prior
consent, then the patient or surrogate must be informed
completely of the experimental nature of the surgery and
the uncertainty of outcome at the first reasonable opportu-
nity. This practice is common and well-observed among
surgeons. Because of the unpredictability of the procedure
and its outcome, the adequacy of the informed consent
process is essential. It must make clear the limits of what is
known and the relatively high degree of uncertainty. One
must disclose that the types and rate of complications are
uncertain as well. These considerations eliminate Options B
and C as inadequate to the purpose.
Tailoring surgical therapy to rare diseases for which
there is no standard treatment may be seen as experimen-
tation, but its intent is clinical rather than scientific. The
unusual nature of the proposed procedure imposes addi-
tional obligations to ensure the patient’s full prior under-
standing, but not the approval of a scientific review panel or
an ethics advisory board, eliminating answers D and E. The
now-venerable Belmont Report distinguishes between clin-
ical practice and research on the basis of the clinician’s
intent.5 “Practice” refers to interventions that are designed
solely to enhance the well-being of an individual patient
and that have a reasonable expectation of success. Innova-
tion which “departs in a significant way from standard or
accepted practice” is experimental, but becomes researchonly when its scope extends beyond the individual patient
by producing generalizable knowledge.
There is no intent to include this patient in a series for
purposes of systematically developing a new body of knowl-
edge or surgical technique for future application to others
with similar conditions; the intent is solely to provide
clinical care. All associated clinical decisions are based en-
tirely upon this patient’s clinical indications; clinical options
will not be limited by conformity to a standard research
protocol and there will be no effort to establish scientific
controls to produce replicable results. Since surgeon/pa-
tient autonomy is the cornerstone of legitimacy in experi-
mentation, the completeness of consent is the single most
important ethical consideration,6 and Option A is the most
appropriate response.
Some would propose that review of such therapies be
mandatory, and we would agree if the procedure is used to
treat diseases that are likely to be encountered repeatedly,
but not for treatment of rare conditions as the present case.
A surgeon, especially one newly-minted, might be wise to
informally consult with the surgeon-in-chief for future
political support, but since all surgeons should be compe-
tent technically and none would be likely to have experi-
ence with the case described, consultation would be ex-
pected to add little.
The Belmont Report suggests that radically new surgi-
cal procedures be made the objects of structured research
soon after their introduction for purposes of scientific eval-
uation. The widespread occurrence of severe bile duct
injuries following the unregulated combination of two
established procedures, cholecystectomy and laparoscopy
to become laparoscopic cholecystectomy, is an oft-cited
example.1 Radically different surgical procedures applied
without oversight when well-established effective methods
are available are sharply criticized in the ethics literature.
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